Loading
Latest filing published 19 Nov 2021 for Flexion Therapeutics Inc, €2.5M. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Michael D. Clayman, listed as chief executive, appears in our data through filings on Flexion Therapeutics Inc shares, published by SEC (Form 4). Between 21 June 2021 and 19 November 2021, the trades on record add up to 3 filings.
None of the filings is a plain purchase or sale on the open market; they cover grants, option exercises and other movements. Such operations are usually part of compensation schedules, which makes them a weaker signal than an open-market trade.
Most recently, on 19 November 2021, the filings show a transaction worth €2.5M in Flexion Therapeutics Inc. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
3 of 3 declarations